Navigation Links
Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
Date:6/2/2008

LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced today the results of the vote of its shareholders on the two proposals put to the shareholders at its Annual Meeting of Shareholders held Friday, May 30, 2008.

The first proposal related to the re-election of each of the six sitting directors of the Company to serve an additional term of one year or until their successors are duly elected and qualified. All six directors were re-elected by the requisite vote of the shareholders.

The second proposal related to the approval of a reverse stock split to be effected at a ratio of ten shares to one share of our common stock. As disclosed in the Company's proxy statement related to the Annual Meeting, the Company has determined that in order to obtain additional financing to further the development of Oxygent(TM), the Company's outstanding indebtedness must be converted into common stock. The holders of substantially all of this outstanding indebtedness have agreed to convert such debt into common stock at a conversion price of $0.17 per share. The material conditions to such conversion are: (i) that the company effect a reverse stock split in a ratio of ten shares of common stock to one share of common stock in order to allow for enough authorized but unissued common stock to enable such conversion; and (ii) that the Company raise at least $3 million in new financing from investors.

The shareholders of the Company approved the reverse stock split by the requisite vote. The Board of Directors of the Company is now authorized to set an effective date for the reverse stock split, and such reverse stock split will become effective on such date and at the time the Company files an amendment to its Articles of Incorporation effecting such reverse stock split. The Company expects that its Board of Directors will set the effective date of the reverse stock split in the near future.

Oxygent Development Update

Alliance has been transferring the manufacturing technology to enable its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane) to manufacture Oxygent in China. To date, Double-Crane has built out the manufacturing facility and has ordered the key equipment, such as tanks, process mixers, pumps, etc. It has also produced the Active Pharmaceutical Ingredient (API), perfluorooctylbromide, in pilot scale quantities. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the SFDA, which is anticipated to be completed in 2008. Alliance has provided Double-Crane Phase 1 and Phase 2 with clinical trial protocols for translation and eventual submission.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary perfluorochemical technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB. Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Alliance Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
2. Lung Cancer Alliance Commends NCCN on Screening Guidelines
3. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
Breaking Medicine News(10 mins):